Actively Recruiting

Age: 12Years +
All Genders
NCT07153666

A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo

Led by Peking University Third Hospital · Updated on 2026-01-02

170

Participants Needed

1

Research Sites

107 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Vitiligo is a common chronic autoimmune skin disease that can occur on any part of the body and severely impacts patients' quality of life. Current treatment for vitiligo primarily include topical medications, phototherapy, systemic therapy and surgical interventions, but their efficacy is limited, often failing to achieve ideal therapeutic outcomes, and are associated with a high recurrence rate. This study is an investigator-initiated real-world research on the application of ruxolitinib cream for vitiligo treatment, with the primary objective of exploring the factors influencing the efficacy of ruxolitinib cream in treating vitiligo.

CONDITIONS

Official Title

A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo

Who Can Participate

Age: 12Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 12 years or older, any gender
  • Signed informed consent form
  • Clinically diagnosed with non-segmental vitiligo
  • Vitiligo area less than 10% of body surface area
  • Agreed to stop all other vitiligo treatments from screening until final follow-up
  • Female participants must not plan pregnancy or oocyte donation from screening until 4 weeks after last dose and must use effective physical contraception
  • Male participants must not plan fertility or sperm donation during the same period and must use effective physical contraception, including barrier methods, intrauterine devices/systems, surgical sterilization performed at least 6 months prior, or other investigator-approved methods
Not Eligible

You will not qualify if you...

  • Allergy to ruxolitinib cream
  • Pregnant or lactating women
  • Any condition the investigator considers unsuitable for study participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Peking University Third Hospital

Beijing, China, 100191

Actively Recruiting

Loading map...

Research Team

J

Jinzhu Guo, MD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here